- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03435315
Treadmill Exercise in Metabolic Syndrome
20. maj 2022 opdateret af: Gloria Y. Yeh, Beth Israel Deaconess Medical Center
The main purpose of this study is to better understand the effects of two types of treadmill exercise programs that include education and/or techniques that may be helpful for exercise among individuals with, or at risk for, metabolic syndrome.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
12
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02215
- BIDMC
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 65 år (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Referred by healthcare provider and given medical clearance for moderate-intensity exercise
Metabolic syndrome, defined as meeting three or more of the following criteria:
- Obesity or overweight defined as BMI > 25
- Impaired glycemia (fasting blood sugar of ≥ 100 [5.6 mmol/L] or glycated hemoglobin [A1C] of ≥ 5.7)
- Increased blood pressure (130/85 mmHg or higher) or if you take medicine for high blood pressure
- Increased fasting levels of triglycerides (≥ 150 or 1.7 mmol/L) or decreased fasting high-density lipoprotein (HDL) cholesterol (less than 40 mg/dL or 1 mmol/L for men or 50 mg/dL or 1.3 mmol/L for women) or if you take any medicines for dyslipidemia
- Between the ages of 18-65
- No regular physical activity (≥ 3 or more days per week) for the past 3 months
Exclusion Criteria:
- Contraindications for treadmill exercise determined by their physician (e.g., cardiopulmonary limitations or diagnoses) or other inability to do treadmill exercise (e.g., musculoskeletal restrictions or severe balance impairment)
- Confirmed diagnosis of coronary artery disease
- Confirmed diagnosis of diabetes
- Currently taking a beta blocker or calcium channel blocker medication
- Uncontrolled and untreated hypertension, defined as a resting blood pressure of 150/90
- Confirmed diagnosis of chronic obstructive pulmonary disease or other severe lung dysfunction that may interfere with exercise (e.g., severe asthma)
- Self-reported psychotic disorder
- Current practice of mindfulness mediation or mindful movement (e.g., yoga or tai chi), defined as regular daily practice or >2 classes or self-guided sessions per week in the past three months.
- Non-English speaking
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Andet
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Løbebåndsøvelse
|
12-session, 6-week traditional treadmill exercise program
|
|
Eksperimentel: Treadmill exercise with behavioral techniques
|
12-session, 6-week treadmill exercise program utilizing behavioral techniques while walking
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Recruitment Feasibility
Tidsramme: Through study completion, an average of 1 year
|
% willing to be randomized
|
Through study completion, an average of 1 year
|
|
Protocol Adherence
Tidsramme: Through study completion, an average of 1 year
|
% sessions attended
|
Through study completion, an average of 1 year
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Cardiopulmonary Dynamics
Tidsramme: Weeks 1 and 6
|
CardioPulmonary Exercise Testing (standard metabolic cart)
|
Weeks 1 and 6
|
|
Fatigue
Tidsramme: Week 0, week 3, post-intervention (after 6 week intervention)
|
Fatigue Severity Scale-7; total score range: 7-49, higher scores = greater fatigue severity
|
Week 0, week 3, post-intervention (after 6 week intervention)
|
|
Global Health
Tidsramme: Week 0, week 3, post-intervention (after 6 week intervention)
|
PROMIS Global Health-10; Global physical health total score range: 4-20, higher scores = better global physical health
|
Week 0, week 3, post-intervention (after 6 week intervention)
|
|
Psychological Symptoms
Tidsramme: Week 0, week 3, post-intervention (after 6 week intervention)
|
Depression Anxiety and Stress Scale-21; Depression total score range: 0-21, higher scores = greater depressive symptoms
|
Week 0, week 3, post-intervention (after 6 week intervention)
|
|
Affect
Tidsramme: Week 0, week 3, post-intervention (after 6 week intervention)
|
Positive and Negative Affect Schedule; 2 subscales; each with score range 10-50, higher = greater positive or negative affect
|
Week 0, week 3, post-intervention (after 6 week intervention)
|
|
Anxiety Sensitivity
Tidsramme: Week 0, week 3, post-intervention (after 6 week intervention)
|
Anxiety Sensitivity Index-3; Total score range: 0-72, higher scores = higher levels of anxiety sensitivity
|
Week 0, week 3, post-intervention (after 6 week intervention)
|
|
Distress Tolerance
Tidsramme: Week 0, week 3, post-intervention (after 6 week intervention)
|
Distress Tolerance Scale; total score range: 15-75, higher scores = higher levels of distress tolerance
|
Week 0, week 3, post-intervention (after 6 week intervention)
|
|
Discomfort Intolerance
Tidsramme: Week 0, week 3, post-intervention (after 6 week intervention)
|
Discomfort Intolerance Scale-Revised; total score range: 0-126, higher scores = higher levels of discomfort intolerance
|
Week 0, week 3, post-intervention (after 6 week intervention)
|
|
Physical Activity Acceptance
Tidsramme: Week 0, week 3, post-intervention (after 6 week intervention)
|
Physical Activity Acceptance Questionnaire; total score range: 10-70, higher scores = greater physical activity acceptance
|
Week 0, week 3, post-intervention (after 6 week intervention)
|
|
Exercise Self-Efficacy
Tidsramme: Week 0, week 3, post-intervention (after 6 week intervention)
|
Multidimensional Self-Efficacy Scale; total score range: 0-90, higher scores = higher levels of exercise self-efficacy
|
Week 0, week 3, post-intervention (after 6 week intervention)
|
|
Exercise Motivation
Tidsramme: Week 0, week 3, post-intervention (after 6 week intervention)
|
Behavioral Regulation towards Exercise Questionnaire-2; 5 subscales, each with score range: 0-16, higher scores = higher levels of regulation
|
Week 0, week 3, post-intervention (after 6 week intervention)
|
|
Exercise Barriers
Tidsramme: Week 0, week 3, post-intervention (after 6 week intervention)
|
Exercise Benefits and Barriers Scale; 2 subscales; Exercise benefits subscale score range: 29-116, higher scores = higher perceived benefit from exercise; Exercise barriers subscale score range: 14-56, higher scores = higher perceived barriers to exercise
|
Week 0, week 3, post-intervention (after 6 week intervention)
|
|
Physical Activity
Tidsramme: Week 0, week 3, post-intervention (after 6 week intervention)
|
Godin Leisure Time Exercise Questionnaire; open-ended responses, higher scores = greater activity time
|
Week 0, week 3, post-intervention (after 6 week intervention)
|
|
Trait Mindfulness
Tidsramme: Week 0, week 3, post-intervention (after 6 week intervention)
|
Five Facet Mindfulness Questionnaire; 5 subscales; Observe subscale score range: 8-40, higher scores = greater observing skills; Describe subscale score range: 8-40, higher scores = greater describing skills; Acting with Awareness subscale score range: 8-40, higher scores = greater awareness skills; Nonjudgment subscale score range: 8-40, higher scores = greater nonjudgment skills; Nonreactivity subscale score range: 7-35, higher scores = greater nonreactivity skills
|
Week 0, week 3, post-intervention (after 6 week intervention)
|
|
State Mindfulness
Tidsramme: Weeks 1, 3, 6
|
State Mindfulness Scale for Physical Activity; 2 subscales, each with score range: 0-24, higher scores = higher levels of mindfulness
|
Weeks 1, 3, 6
|
|
Interoceptive Awareness
Tidsramme: Week 0, week 3, post-intervention (after 6 week intervention)
|
Multidimensional Assessment of Interoceptive Awareness; 8 subscales, each with score ranges: 0-5, higher scores = better
|
Week 0, week 3, post-intervention (after 6 week intervention)
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
9. januar 2019
Primær færdiggørelse (Faktiske)
7. juli 2021
Studieafslutning (Faktiske)
20. oktober 2021
Datoer for studieregistrering
Først indsendt
23. januar 2018
Først indsendt, der opfyldte QC-kriterier
9. februar 2018
Først opslået (Faktiske)
19. februar 2018
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
26. maj 2022
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
20. maj 2022
Sidst verificeret
1. maj 2022
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 2018P000014
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Metabolisk syndrom
-
Consorcio Centro de Investigación Biomédica en...Hospital General Universitario Gregorio Marañon; Universidad Complutense... og andre samarbejdspartnereIkke rekrutterer endnuLeverfibrose/NASH | MASH - Metabolic Dysfunction-Associated Steatohepatitis | MASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseSpanien
-
Rivus Pharmaceuticals, Inc.RekrutteringMASH - Metabolic Dysfunction-Associated SteatohepatitisForenede Stater
-
Madrigal Pharmaceuticals, Inc.RekrutteringMASH - Metabolic Dysfunction-Associated SteatohepatitisForenede Stater
-
Shanghai East HospitalRekrutteringMASH - Metabolic Dysfunction-Associated SteatohepatitisKina
-
Southern California Institute for Research and...Ikke rekrutterer endnuMASH - Metabolic Dysfunction-Associated Steatohepatitis
-
Nabiqasim Industries (Pvt) LtdRekrutteringMASH - Metabolic Dysfunction-Associated SteatohepatitisPakistan
-
Fondazione Policlinico Universitario Agostino Gemelli...RekrutteringMASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseItalien
-
Tangram Therapeutics PlcRekrutteringSunde deltagere | MASH - Metabolic Dysfunction-Associated SteatohepatitisDet Forenede Kongerige
-
University of Campania Luigi VanvitelliAfsluttetMASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseItalien
-
University Hospital, Basel, SwitzerlandIkke rekrutterer endnuKardiovaskulær-Kidney-metabolsk syndrom | Cradiovascular-Kidney-Liver-Metabolic (CKLM) syndromSchweiz